Sumitomo Chemical's F3/26 results return to a growth trajectory, with Morgan Stanley seeing further upside

Overview

This is a Morgan Stanley earnings review on Sumitomo Chemical (4005.T) for F3/26. The core conclusion is that the company has returned to a growth trajectory: F3/26 core operating profit was above both company guidance and Morgan Stanley's forecast, and the F3/27 company guidance still points to profit growth even after factoring in the deterioration in Middle East conditions. Morgan Stanley remains positive and believes valuation is still attractive even after the stock surged sharply on the day of the results release.

Core views

The report's key views are: first, F3/26 was of good quality, as pharmaceutical and petrochemical improvements supported base core operating profit despite weaker ICT-related earnings; second, F3/27 growth drivers include better profitability in pharmaceuticals, agrochemicals, ICT, and petrochemicals; third, improved refining margins at Petro Rabigh could provide additional upside for the petrochemical business; fourth, the company's agrochemical products such as Indiflin and biorationals still have growth potential, while the ICT business is building a structure around AI-driven transformation in semiconductor materials; fifth, the higher dividend plan strengthens the signal of shareholder returns.

Analysis framework

The report compares actual results, company guidance, market consensus, and Morgan Stanley forecasts, and then assesses upside based on segment profitability trends, business strategy commentary, and valuation methods. On valuation, it uses an SOTP framework and references peer-average P/E multiples for different business segments, while also incorporating the target price impact of Sumitomo Pharma (4506).

Methodology notes

• Valuation methodsSOTP

  sum-of-the-parts valuation

  Morgan Stanley says it uses SOTP valuation for petrochemical majors to reflect their broad business scope; the segment P/E references are peer-average levels, with Agro & Life Solutions at 12.0x, ICT & Mobility Solutions at 12.0x, and Essential & Green Materials at 7.5x.

• Valuation methodsP/E and P/B

  F3/28e EPS ¥80.0, 10.6x P/E, and 1.3x P/B

  The report discloses that the target price method uses F3/28e EPS and valuation multiples, and also references P/B levels as a valuation benchmark.

• ratingMorgan Stanley Overweight

  relative-return rating

  Overweight means that over the next 12-18 months, the stock's total return is expected to exceed the average of the analyst's covered universe on a risk-adjusted basis.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sumitomo Chemical (4005.T)

  core coverage name

  Strengths

  Core operating profit beat expectations, F3/27 profit growth guidance is solid, the dividend plan was raised, and the valuation still has upside to the target price.

  Weaknesses

  F3/26 sales fell by about 10.7% YoY, some ICT-related profits declined, and the business spans multiple cyclical and non-cyclical segments.

  Comparison

  The rating is Overweight, above Mitsubishi Chemical Group and Tosoh, which are rated Equal-weight in the covered peer group.

  Risks

  A sharper-than-expected deterioration in LCD material demand, PRC operating issues, yen appreciation, production equipment problems, and worsening Middle East conditions.

• Sumitomo Pharma (4506)

  valuation reference and important segment

  Strengths

  It contributed significantly to segment operating profit in F3/26, and the report incorporates its target price in the SOTP valuation.

  Weaknesses

  The pharmaceutical business may be affected by product cycles, R&D, and regulatory factors.

  Comparison

  As a standalone reference item within Sumitomo Chemical's valuation, it influences group valuation together with the agrochemical, ICT, and materials businesses.

  Risks

  Competition in the pharmaceutical market, R&D failures, regulatory approvals, and earnings volatility.

• Petro Rabigh

  upside source for the petrochemical business

  Strengths

  Improving refining margins are seen by the report as a potential upside factor for the F3/27 petrochemical business.

  Weaknesses

  Profitability is highly sensitive to the refining cycle, feedstock prices, and regional supply-demand conditions.

  Comparison

  Compared with other segments, the petrochemical business is more affected by external commodity cycles and Middle East conditions.

  Risks

  Deterioration in Middle East conditions, narrowing refining spreads, and production or operating issues.

Key data

• Stock ratingOverweightThe report chart shows the industry view as Attractive.
• Target price¥850Compared with the 2026-05-14 closing price of ¥604, the implied upside is about 40.7%.
• F3/26 core operating profit¥208.376bnAbove company guidance of ¥200bn and Morgan Stanley's forecast of ¥203bn.
• F3/27 company core operating profit guidance¥215bnUp 3% YoY, and already includes about ¥10bn of negative impact from deteriorating Middle East conditions.
• F3/27 Morgan Stanley net profit forecast¥100bnAbove company guidance of ¥70bn and consensus of about ¥79.486bn.
• F3/27 dividend plan¥24The company said it hopes to restore the dividend to ¥24 per share as soon as possible.
• Market cap¥986.8bnFrom the report's key data chart.

Impact & implications

The report is positive for investment implications: the earnings beat, the possibility of further guidance upgrades, and a clear dividend-recovery target, together with substantial upside remaining versus the current share price, support the Overweight rating. If Petro Rabigh refining margins continue to improve, the petrochemical segment could become an additional catalyst; meanwhile, the agrochemical and semiconductor-materials-related ICT initiatives provide support for medium-term growth.

Risks

• If supply-demand and pricing for key petrochemical products fall short of expectations, earnings improvement could weaken.
• A sharp drop in LCD material demand could drag on ICT-related profits.
• PRC operating issues and production equipment problems could affect utilization rates and costs.
• Yen appreciation creates earnings pressure; the report notes that every ¥1 appreciation against the US dollar reduces annual operating profit by about ¥2.0bn, and the assumption from F3/27 onward is ¥150/USD.
• The company has already incorporated about ¥10bn of negative impact from deteriorating Middle East conditions, but further deterioration could still create additional risk.
• Morgan Stanley has potential conflicts of interest with covered companies, including investment banking business and shareholdings, so investors should make an independent assessment.

What to watch

• Whether F3/27 core operating profit guidance is revised upward.
• Whether Petro Rabigh refining margins and petrochemical profitability can continue to improve.
• The pace of growth for agrochemical products Indiflin and biorationals.
• Progress in the ICT and semiconductor materials business transformation around AI demand.
• Whether the company can restore the dividend to ¥24 per share as soon as possible.
• Changes in the yen exchange rate, Middle East conditions, and LCD material demand.